[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-risk":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,63,90,118,148,204,225,251,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100577907","canscan-community-based-registry-to-assess-address-and-advance-screening-for-cancer-prevention-and-management-100577907",false,"NCT06804395","CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management","* Adults ( 18 and older)\n* Ability to provide own consent\n* Must meet at least one of the below criteria, Indicating an increased risk for cancer, any of the following:\n\n  * Family or personal history suggests a familial\u002Fhereditary disorder known or suspected of predisposition to cancer.\n  * Personal factors associated with an increased risk for cancer include benign breast disease, polyps, tobacco use, etc.as defined by the investigator.\n  * Family members of participating individuals.\n* Any participant in the HICAP program regardless of cancer risk",true,"ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Early diagnosis of cancer allows for better treatment outcomes, higher survival rates, and lower costs of care. It is shown that cancer monitoring for cancer in at-risk populations is a key component in early diagnosis. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science (HICAP) is a newly founded institute, providing clinical services for cancer screening and risk assessment to the community, as well as research in cancer risk and prevention. The CanScan registry will prospectively collect data from participants in the form of questionnaires. The registry will also capture data that is collected as per non-research assessments, for participants who consent to participate. The registry will facilitate better understanding of cancer risk, screening, and diagnostics.",[25],"Cancer Risk",[27,25,28,29],"Cancer Prevention","Cancer Early Detection","Cancer High Risk","RECRUITING","2026-05-21",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2024-10-01",{"date":38,"type":20},"2034-10-01",{"name":40,"class":41},"Hackensack Meridian Health","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":42},"100283474","norris-orien-total-cancer-care-100283474","NCT02970045","Norris ORIEN Total Cancer Care","Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership With Patients","Inclusion Criteria:\n\n* Limited to those patients who are registered for outpatient or inpatient care at University of Southern California (USC) Norris\n* Able to understand and sign the TCCP informed consent, California subject's bill of rights, Health Insurance Portability and Accountability Act (HIPAA), and research authorization form directly or through an authorized representative; the informed consent, subject's bill of rights, HIPAA, and research authorization will be available in both English and Spanish languages\n\nExclusion Criteria:\n\n* Individuals who are not registered as patients for outpatient or inpatient care at USC Norris\n* Individuals who are unable to understand or sign the TCCP informed consent, subject's bill of rights, HIPAA, and research authorization in either English or Spanish",{"count":19,"type":20},"This research trial collects biological samples and clinical information to create a repository of data from patients with cancer or a predisposition for cancer. Combining genetic information from biological samples and clinical data may lead to more knowledge about why certain cancers respond to treatment and help create more personalized medicine.",[25,53],"Malignant Neoplasm","2026-04-24",{"date":56,"type":34},"2026-04-29",{"date":58,"type":34},"2016-05-02",{"date":60,"type":20},"2037-05-02",{"name":62,"class":41},"University of Southern California",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":42},"100634705","clinical-biospecimen-collection-100634705","NCT07543159","Clinical Biospecimen Collection","New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use","(NYCBS)","Inclusion Criteria:\n\n1. Subjects must be at least 18 years of age\n2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent\n3. Subjects may or may not have active disease at the time of enrollment\n4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.\n\nExclusion Criteria:\n\n4\\) Subjects not meeting the inclusion criteria\n\nAdditional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.",{"count":72,"type":20},900000,"New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.",[25],[76,77,78,79,80,81],"New York Cancer","Oncology","Cancer","Clinical Trial","Biobank","Umbrella","2026-04-21",{"date":54,"type":34},{"date":85,"type":34},"2025-12-23",{"date":87,"type":20},"2035-10-06",{"name":89,"class":41},"North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100333179","a-lifetime-partnership-with-patients-who-have-or-may-be-at-risk-of-having-cancer-100333179","NCT03617939","A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer (ORIEN)","Inclusion Criteria:\n\n1. 18 years of age and older.\n2. Diagnosed with cancer, or may be at risk for cancer.\n3. Able to understand and sign the TCCP Informed Consent and Research Authorization form directly or through a legally authorized representative (LAR).\n\nNon-English speaking subjects will also be invited to participate in the TCCP study, in accordance with COMIRB's short-form consent use.\n\nExclusion Criteria:\n\n1\\. Members of vulnerable populations including neonates (birth to 30 days), children (under age 18), wards of the State, prisoners or those on probation or alternate sentencing, or decisionally challenged (adults or children that are cognitively impaired, incompetent to consent, proxy consent, or consenting in life threatening situations).",{"count":98,"type":20},20000,"This is not a treatment study. The overall objective is to develop an improved standard of care through studying blood, tissue, biological, etc. samples, that patients have allowed researchers to procure.",[25],[102,103,104,105,106,107],"Tissue Repository","Blood Samples","Biological Samples","Surveys","Early Detection","Risk Assessment","2025-11-06",{"date":110,"type":34},"2025-11-10",{"date":112,"type":34},"2015-09-16",{"date":114,"type":20},"2037-09",{"name":116,"class":41},"University of Colorado, Denver",6,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":15,"sex":125,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100602320","mirai-mri-validation-of-ai-models-for-breast-cancer-risk-100602320","NCT07121972","Mirai-MRI: Validation of AI Models for Breast Cancer Risk","Mirai-MRI: Multi-site Prospective Validation of AI Models for Breast Cancer Risk","Inclusion Criteria:\n\n1. All asymptomatic participants assigned female at birth, ages 40-89 years old with screening mammography assessed as Breast Imaging Reporting and Data System (BI-RADS) 1, BI-RADS 2, or initial BI-RADS 0 with subsequent diagnostic mammogram assessed as BI-RADS 1 or BI-RADS 2.\n2. Screening mammogram assessed as high-risk by Mirai (top 3 percentile of 2-year risk).\n3. Availability of a routine screening mammogram report, along with a subsequent diagnostic mammogram report if applicable, and access to the corresponding Digital Imaging and Communications in Medicine (DICOM) images.\n4. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Screening mammogram that is assessed as BI-RADS 0 for technical recall.\n2. Contraindications for MRI:\n\n   1. Metallic foreign body in the eye.\n   2. MRI unsafe implants and\u002For medical devices.\n   3. Adverse reaction to a (gadolinium-based) contrast agent in the past.\n   4. Pregnant women.\n   5. Claustrophobia.\n   6. Exceeds site specific size and\u002For weight limit for MRI.\n3. If the participant meets site-specific criteria for screening estimated glomerular filtration rate (eGFR) prior to MRI, participants with severely impaired renal function (GFR \\\u003C 30 mL\u002Fmin) will be excluded. According to University of California, San Francisco's policy for MRI with contrast (gadolinium-containing), serum creatinine with calculation of eGFR should be obtained within 6 weeks of the MRI study for participants with any of the following risk factors:\n\n   1. History of \"kidney disease\" as an adult, including renal tumor or transplant.\n   2. Diabetes treated with insulin or other prescribed medications.\n   3. Hypertension (high blood pressure) requiring medication.\n   4. Multiple myeloma.\n   5. Solid organ transplant.\n   6. History of severe hepatic disease\u002Fliver transplant\u002Fpending liver transplant.","FEMALE","40 Years","89 Years",{"count":129,"type":20},400,"INTERVENTIONAL",[132],"NA","This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.",[25,135],"Breast Cancer Risk",[137,138],"Screening","BI-RADS","2025-11-04",{"date":108,"type":34},{"date":142,"type":34},"2025-11-03",{"date":144,"type":20},"2027-01-31",{"name":146,"class":41},"University of California, San Francisco",4,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":22,"phases":4,"briefSummary":158,"conditions":159,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":42},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891","NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",{"count":156,"type":20},5000,"20 Years","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[25,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189],"Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Childhood Cancer Survivors","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Lung Cancer","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Hematologic Malignancy","Lung; Node","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[191,192,193,194],"Hereditary Risk for Cancer","Childhood cancer survivors","Adult cancer survivors","Precursor Lesions","2025-08-04",{"date":197,"type":34},"2025-08-07",{"date":199,"type":34},"2023-04-25",{"date":201,"type":20},"2032-03-25",{"name":203,"class":41},"Dana-Farber Cancer Institute",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":42},"100360766","total-cancer-care-protocol-a-lifetime-partnership-with-patients-who-have-or-may-be-at-risk-of-having-cancer-100360766","NCT03977402","Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","TCCP","Inclusion Criteria:\n\n* 18 years of age and older.\n* Has a diagnosis of cancer or is suspected of having cancer.\n* Able to understand and sign the Informed Consent form directly.\n* Pregnant women are permitted to be enrolled.\n\nExclusion Criteria:\n\n* Prisoners",{"count":213,"type":20},47500,"The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new cancer research, clinical trials, new technology, new informatics solutions, and \"personalized medicine\" for the University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Oncology Research Information Exchange Network (ORIEN) Consortium of academic medical centers, community hospital systems, and other health care providers. To bring new translational research to the community, the ORIEN consortium has initiated the ORIEN Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.",[78,25],"2025-05-20",{"date":218,"type":34},"2025-05-22",{"date":220,"type":34},"2016-01-27",{"date":222,"type":20},"2037-12-31",{"name":224,"class":41},"New Mexico Cancer Research Alliance",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":42},"100566307","development-and-demonstration-of-intelligent-assessment-based-on-multi-modal-information-fusion-for-tumor-risk-and-diagnosis-and-treatment-100566307","NCT06653478","Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment","Inclusion Criteria:\n\n1. Participants with the suspected of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision\n2. Participants that have signed informed consent.\n3. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.\n4. Healthy participants with no clinical diagnosis of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision.\n\nExclusion Criteria:\n\n1. Participants with primary clinical and pathological data missing.\n2. Participants lost to follow-up.\n3. Participants with too poor medical image quality to perform segment and mark ROI accurately","75 Years",{"count":233,"type":20},3000,"To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.",[236,237,166,180,238,239,25,240,241],"Artificial Intelligence","Deep Learning","Stomach Cancer","Colon Cancer","Cancer Screening","Cancer, Treatment-Related","2024-10-20",{"date":244,"type":34},"2024-10-22",{"date":246,"type":34},"2022-06-01",{"date":248,"type":20},"2026-10-01",{"name":250,"class":41},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":234,"conditions":258,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":263,"leadSponsor":265,"locationsCount":42},"100471996","artificial-intelligence-system-for-assessment-of-tumor-risk-and-diagnosis-and-treatment-100471996","NCT05426135","Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment","Development of an Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment Based on Multimodal Data Fusion Using Deep Learning Technology",{"count":233,"type":20},[236,237,166,180,238,239,25,240,241],"2022-06-17",{"date":261,"type":34},"2022-06-21",{"date":246,"type":34},{"date":264,"type":20},"2026-10",{"name":250,"class":41},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":274,"targetDuration":275,"studyType":22,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":42},"100424283","morehouse-total-cancer-care-protocol-100424283","NCT04804878","Morehouse Total Cancer Care Protocol","Morehouse Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","MSMTCC","Inclusion Criteria:\n\n1. 18 years of age and older.\n2. Diagnosed with cancer, or at risk for cancer. This includes anyone in the general population, but our primary focus will be on patients with a cancer diagnosis.\n3. Able to understand and sign the TCCP Informed Consent and Research Authorization form directly or through an authorized representative. The Informed Consent and Research Authorization will be available in both English and Spanish languages\n\nExclusion Criteria:\n\nNone\n\n\\-",{"count":156,"type":20},"5 Years","The overall objective of the Morehouse Total Cancer Care study is to develop an improved standard of cancer care by facilitating new biomarker and drug target discovery, informatics solutions, clinical trials, and \"personalized medicine\" for our community oncology partners (i.e., community hospital systems, and other cancer care providers). To bring new translational research to the community, Morehouse School of Medicine has initiated the Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of African American cancer patients, survivors, or those at risk of having cancer. This is not a treatment trial, but a longitudinal study designed to create a centralized cancer biorepository for precision medicine.",[78,25],"2021-03-16",{"date":280,"type":34},"2021-03-18",{"date":282,"type":34},"2018-04-05",{"date":284,"type":20},"2037-04",{"name":286,"class":41},"Morehouse School of Medicine"]